Indeed. I wonder though, with the P2 and P3 trials in Canada - can this data and the findings also be used to support TGA approval in Australia? Or would CPH need to conduct its own local trials to support use of psilocybin as a therapy here?
- Forums
- ASX - By Stock
- CPH
- Ann: Halucenex Secures Additional Pharmaceutical Grade Psilocybin
Ann: Halucenex Secures Additional Pharmaceutical Grade Psilocybin, page-106
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online